ETFS Holding Actavis Inc

 
ETF Quotes for ETFS Holding Actavis Inc top ^
  • Holdings: Southwest Airlines Co , Vertex Pharmaceuticals Inc , Keurig Green Mountain Inc , Celgene Corp , Actavis PLC ,
  • Morningstar Rating: 5 Stars
Sign-up for rpg investment picks
  • Holdings: Medivation Inc , Actavis PLC , Cooper Companies , Illumina Inc , Gilead Sciences Inc ,
  • Morningstar Rating: 2 Stars
Sign-up for pth investment picks
  • Holdings: AmerisourceBergen Corp , Centene Corp , Medivation Inc , Actavis PLC , Aetna Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for fxh investment picks

 
News Articles for Actavis Inc top ^
DUBLIN , Sept.
Sign-up for Actavis Confirms Generic Butrans® Patent Challenge investment picks
Actavis PLC (ACT) reportedly is in talks to purchase Salix Pharmaceuticals Ltd.
Sign-up for Actavis reportedly in talks to buy Salix Pharma investment picks
By Jonathan D.
Sign-up for Pfizer held takeover talks with Actavis investment picks
Shares of Actavis Plc (ACT) rose more than 2% in afternoon trade Tuesday, after Bloomberg News reported that the company was approached by Pfizer Inc. (PFE) to discuss a possible deal.
Sign-up for Actavis shares rise on report of Pfizer approach investment picks
By Jonathan D.
Sign-up for Botox maker Allergan rejected Actavis takeover bid investment picks
DUBLIN , Sept.
Sign-up for Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast investment picks
ROCKVILLE, Md., Oct.
Sign-up for Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Actavis plc (NYSE: ACT) announced today that the following linaclotide-related data will be presented during the American College of Gastroenterology 2014 Annual Scientific Meeting in Philadelphia, October 17 through October 22, 2014.
Sign-up for Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting investment picks
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Durata Therapeutics Inc. (Nasdaq:DRTX) (“Durata”) in connection with the sale of the Company to Actavis (NYSE: ACT). Click here to learn about the case: http://docs.wongesq.com/DRTX-Info-Request-Form-431 .
Sign-up for INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata Therapeutics Inc. Regarding the Fairness of the Sale of the Company to Actavis investment picks
Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. (“Durata” or “the Company”) (NASDAQ:DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE: ACT). Click here to learn more about the investigation: http://zlk.9nl.com/durata-therapeutics-drtx .
Sign-up for INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis investment picks
2014/10/6
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. (“Durata”) (NasdaqGM: DRTX) concerning the acquisition by Actavis.
Sign-up for DURATA THERAPEUTICS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Actavis investment picks
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Durata Therapeutics, Inc. (NASDAQ:DRTX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Durata to maximize shareholder value before agreeing to be acquired by Actavis plc (NYSE:ACT). If you would like to join the action, go to http://rosenlegal.com/cases-387.html or contact Phillip Kim or Kevin Chan, toll-free at 866-767-3653, or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com .
Sign-up for EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX investment picks
2014/10/6
By Tess Stynes Actavis PLC reached an agreement to acquire specialty pharmaceutical company Durata Therapeutics Inc. in a deal the companies valued at about $675 million, which is expected to strengthen Actavis's business that focuses on infectious diseases.
Sign-up for Actavis agrees to acquire Durata Therapeutics investment picks
- Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings - - Enhances Actavis' Long-term Growth Profile 2015+ - - Experienced Development and Commercial Team Bolsters Actavis' Infectious Disease Expertise - - Leverages Actavis' Hospital Sales and Marketing Capabilities - DUBLIN, Ireland and CHICAGO , Oct.
Sign-up for Actavis to Acquire Durata Therapeutics, Inc. investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Actavis Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Acme Packet, Inc.  |  Next: ETFS Holding Actavis PLC